


Bavisant dihydrochloride hydrate

Cat. No.:	HY-14880B
CAS No.:	1103522-80-0
Molecular Formula:	C ₁₉ H ₃₁ Cl ₂ N ₃ O ₃
Molecular Weight:	420.37
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : ≥ 50 mg/mL (118.94 mM)					
	DMSO : ≥ 1 mg/mL (2.38 mM)					
	* "≥" means soluble, but saturation unknown.					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
1 mM			2.3789 mL	11.8943 mL	23.7886 mL	
5 mM			0.4758 mL	2.3789 mL	4.7577 mL	
	10 mM		0.2379 mL	1.1894 mL	2.3789 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 50 mg/mL (118.94 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	Bavisant dihydrochloride hydrate (JNJ31001074AAC) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H ₃ receptor. Bavisant dihydrochloride hydrate can be used for attention-deficit hyperactivity disorder (ADHD) research ^{[1][2][3]} .
IC₅₀ & Target	H ₃ receptor
In Vivo	Bavisant dihydrochloride hydrate increases acetylcholine levels in rat frontal cortex ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

-
- [1]. Ghoshal A, et al. Identification of novel β -lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents. *Eur J Med Chem.* 2018 May 25;152:148-159.
- [2]. Ghamari N, et al. Histamine H3 receptor antagonists/inverse agonists: Where do they go? *Pharmacol Ther.* 2019 Aug;200:69-84.
- [3]. Hudkins RL, et al. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl]propoxy}phenyl]-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. *J Med Chem.* 2011 Jul 14;54(13):4781-92.
- [4]. Weisler RH, et al. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. *CNS Drugs.* 2012 May 1;26(5):421-34.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA